内镜鼻窦术后额外阿片类处方发生率及预测因素
该回顾性研究纳入121例2016年11月至2017年8月接受日间内镜鼻窦手术的慢性鼻窦炎患者,22例(18%)在术后60天内需额外阿片类处方。多因素分析显示术前阿片使用、处方片数较多和术前ASA评分较低与额外处方相关,而手术范围无关。
要点
- 内镜鼻窦术后18%患者需额外阿片类处方。
- 术前阿片使用、处方片数多、ASA评分低预测额外处方。
- 手术范围(窦数、鼻中隔成形、修正或扩大手术)与额外处方无关。
核心结论
- 内镜鼻窦术后需延长阿片类疼痛控制并不少见,患者基线临床特征可预测再处方需求,手术范围与延长术后阿片管理需求无关。
研究设计与样本
- 回顾性综述,纳入2016年11月至2017年8月接受日间内镜鼻窦手术的受试者,共121例,审查医疗和CURES记录,采用单因素和多因素逻辑回归评估术后60天内额外阿片类处方相关因素。
主要发现
- 121例患者中22例(18%)出现额外阿片类处方。
- 手术因素包括手术窦数、鼻中隔成形、修正或扩大手术(Draf IIB/III)与额外处方无关。
- 多因素逻辑回归显示术前阿片使用(OR 23.45;95% CI 1.52-362.63)、处方片数较多(OR 1.13;95% CI 1.01-1.26)和术前健康状态较低(ASA评分)(OR 11.21;95% CI 1.49-84.30)与额外处方相关(p < 0.05)。
临床怎么用
- 对于术前有阿片使用、ASA评分较低或初始处方片数较多的内镜鼻窦手术患者,应关注术后额外阿片类处方需求。
- 手术范围本身不提示延长术后阿片管理的需要,处方决策应基于患者基线特征。
局限性
- 回顾性研究设计,样本量121例,单中心数据,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excessive postoperative opioid prescription is a source of prescription diversion in the United States opioid crisis and may contribute to chronic opioid use. Efficient prescription by the surgeon can mitigate opioid abuse and improve postoperative pain control. In this study we sought to better characterize the incidence and predictive baseline characteristics associated with the need for additional opioid prescription after endoscopic sinus surgery (ESS) for chronic rhinosinusitis. METHODS: A retrospective review was performed on subjects undergoing ambulatory ESS between November 2016 and August 2017. The medical and Controlled Substance Utilization Review and Evaluation System (CURES) records were reviewed. Uni- and multivariable logistic regressions were performed to evaluate factors associated with additional opioid prescription within 60 days of surgery. RESULTS: A total of 121 patients were included. Additional prescriptions were seen in 22 patients (18%). Surgical factors, including sinuses operated, septoplasty, revision, or extended procedure (Draf IIB/III), were not associated with additional prescription. On multivariate logistic regression, preoperative opioid use (odds ratio [OR], 23.45; 95% CI, 1.52-362.63), greater number of prescribed tablets (OR, 1.13; 95% CI, 1.01-1.26), and lower preoperative health status (ASA score) (OR, 11.21; 95% CI, 1.49-84.30) were associated with additional prescription (p < 0.05). CONCLUSION: A need for extension of postoperative opioid pain control is not uncommon after ESS. Patient baseline clinical characteristics are predictive of a need for re-prescription of opioids. Surgical extent is not associated with need for prolonged postoperative opioid pain management.
引用
- Jafari A, Shen SA, Bracken DJ, et al. Incidence and predictive factors for additional opioid prescription after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2018. PMID: 29851273. doi:10.1002/alr.22150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。